Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

BZ-26, A Novel GW9662 Derivate, Attenuated Inflammation By Inhibiting The Differentiation And Activation Of Inflammatory Macrophages.

Yuncheng Bei, J. Chen, F. Zhou, Yahong Huang, N. Jiang, R. Tan, P. Shen
Published 2016 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Peroxisome proliferator-activated receptor-gamma (PPARγ) is considered to be an important transcriptional factor in regulation of macrophages differentiation and activation. We have synthesized a series of novel structural molecules based on GW9662's structure (named BZ-24, BZ-25 and BZ-26), and interaction activity was calculated by computational docking. BZ-26 had shown stronger interaction with PPARγ and had higher transcriptional inhibitory activity of PPARγ with lower dosage compared with GW9662. BZ-26 was proved to inhibit inflammatory macrophage differentiation. LPS-induced acute inflammation mouse model was applied to demonstrate its anti-inflammatory activity. And the results showed that BZ-26 administration attenuated plasma tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) secretion, which are vital cytokines in acute inflammation. The anti-inflammatory activity was examined in THP-1 cell line, and TNF-α, IL-6 and MCP-1, were significantly inhibited. The results of Western blot and luciferase reporter assay indicated that BZ-26 not only inhibited NF-κB transcriptional activity, but also abolished LPS-induce nuclear translocation of P65. We also test BZ-26 action in tumor-bearing chronic inflammation mouse model, and BZ-26 was able to alter macrophages phenotype, resulting in antitumor effect. All our data revealed that BZ-26 modulated LPS-induced acute inflammation via inhibiting inflammatory macrophages differentiation and activation, potentially via inhibition of NF-κB signal pathway.
This paper references
Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma
D. Vara (2013)
PPARs at the crossroads of lipid signaling and inflammation
W. Wahli (2012)
PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
Ajay Chawla (2001)
Monocyte recruitment during infection and inflammation
C. Shi (2011)
Macrophages in atherosclerosis: a dynamic balance
Kathryn J. Moore (2013)
Tumor-associated macrophages: from mechanisms to therapy.
Roy Noy (2014)
Fos Proteins Suppress Dextran Sulfate Sodium-Induced Colitis through Inhibition of NF-κB
Y. Takada (2009)
GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation
J. Seargent (2004)
Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
S. Kamath (2003)
Immunity, Inflammation, and Cancer
S. Grivennikov (2010)
The role of PPARγ in TBBPA-mediated endocrine disrupting effects in human choriocarcinoma JEG-3 cells
Ewelina Honkisz (2015)
The roles of endogenous reactive oxygen species and nitric oxide in triptolide-induced apoptotic cell death in macrophages
Xiaofeng Bao (2006)
Cytokine signaling modules in inflammatory responses.
J. O'Shea (2008)
Thiazolidinediones and PPARγ agonists: time for a reassessment
B. Cariou (2012)
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
A. Ryan (2005)
Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation.
X. Xu (2013)
PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer
G. Murphy (2000)
5-ASA-glutamate protects rats from inflammatory bowel disease induced by intracolonic administration of trinitrobenzensulfonic acid.
C. Clerici (1998)
Peroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis
C. Lee (2002)
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
A. Mantovani (2002)
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.
D. Straus (2007)
Reduced Adipose Tissue Macrophage Content Is Associated With Improved Insulin Sensitivity in Thiazolidinedione-Treated Diabetic Humans
S. Koppaka (2013)
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
G. Pascual (2005)
Reduced activity of mtTFA decreases the transcription in mitochondria isolated from diabetic rat heart.
A. Kanazawa (2002)
Allelic discrimination of factor V Leiden using the GeneAmp 5700 Sequence Detection System.
S. Monk (2002)
Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate.
M. Yamada (2005)
Catalase potentiates retinoic acid‐induced THP‐1 monocyte differentiation into macrophage through inhibition of peroxisome proliferator‐activated receptor γ
Qiurong Ding (2007)
Rosiglitazone‐induced CD36 up‐regulation resolves inflammation by PPARγ and 5‐LO‐dependent pathways
I. Ballesteros (2014)
Activation of NF-κB mediates the PMA-induced differentiation of K562 cells
C. Kang (1998)
Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.
L. Leesnitzer (2002)
Tissue-resident macrophages
Luke C Davies (2013)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar